• Company
    • About
    • Leadership
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • Immuno-Oncology
      • BND-22
      • BND-35
      • BND-67
    • INspire Technology
  • Clinical Trials
  • News
    • Public Relations
    • Events
  • Collaborations
  • Contact Us
  • Company
    • About
    • Leadership
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • Immuno-Oncology
      • BND-22
      • BND-35
      • BND-67
    • INspire Technology
  • Clinical Trials
  • News
    • Public Relations
    • Events
  • Collaborations
  • Contact Us

BND-22

BND-22,  a novel immune checkpoint inhibitor, entered Phase 1/2 trials in Q2 2021 and will be evaluated in advanced cancer patients with no alternative therapies. BND-22, was partnered with Sanofi for $125 million upfront payment, and up to $1 billion in development, regulatory, and sales milestones and double-digit royalties. 

View the 2020 AACR: BND-22 poster

BND-22 enhances the ability of macrophages to phagocytose tumor cells

BND-22 enhances anti-tumor activity of T cells and NK cells

Illustration of the MOA of BND-22: The tumor microenvironment contains macrophages and NK cells that are inhibited through HLA-G-ILT2 interactions (1). Once BND-22 is added, the antibody increases the innate immune response by enhancing both phagocytosis by macrophages and cytotoxicity of NK cells leading to tumor cell destruction and release of tumor antigens (2). These tumor antigens are released and are presented by antigen presenting cells in the periphery (3) which leads to T cell priming, activation and eventually infiltration into the tumor (4). In parallel, BND-22 acts directly on T cells to increase their activation and cytotoxicity in the tumor microenvironment (5). Taken together, this demonstrates the ability of BND-22 to generate a broad anti-tumor response which is mediated by its ability to activate innate and adaptive immune cells.

BND-22 Clinical Development

BND-22-001 is the first-in-human clinical trial of BND-22. It is a Phase 1/2 multicenter, open label, dose escalation and expansion study enrolling advanced cancer patients with select solid tumor types. The study is evaluating the safety and tolerability, maximum tolerated dose/recommended Phase 2 dose (MTD/RP2D), pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BND-22.

The trial will be conducted at several clinical sites, initially enrolling patients in the US and Israel.

View the Clinical Trials page

© Copyright 2020

Designed by YuvalDesign